Understanding immunotherapy and its management

Published On: January 12, 2021 | Pages: 001 - 007

Author(s): Nadiminti Rajesh Kumar* and Sajid Alvi

A few tumours are exceptionally stubborn to oral chemotherapy. The endurance of tumours in a few cases is helped by checkpoint immunomodulation to keep up the unevenness between resistant reconnaissance and disease cell division. Checkpoint counteracting agent inhibitors, for example, against PD-1/PD-L1, are another class of inhibitors that capacity has tumour stifflin ...

DOI: 10.17352/2455-8591.000030